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I In nt tr ro od du uc ct ti io on n: :   Peri-procedural myocardial infarction (PMI) is a frequent and
prognostically important complication of percutaneous coronary intervention
(PCI). This study was designed to determine the predictors of PMI in patients
pre-treated with statins.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   A total of 418 stable angina pectoris patients taking
statins and aspirin were included. All the patients underwent PCI. Serum
concentrations of creatine kinase (CK-MB mass) and troponin I (TnI) were
measured prior to and then within 16 to 24 hours after PCI. The incidence of
PMI was assessed using the established criteria (≥ 3 times upper limit of normal).
R Re es su ul lt ts s: :   Four hundred and eighteen stable patients (63 ﾱ10 years, 68% males)
were treated by PCI. The technical success rate of PCI was 99%. The incidence
of PMI based on CK-MB mass or TnI release was 12% (PMI group). There were
no significant differences in baseline clinical and procedural characteristics
between PMI and non-PMI groups except for the balloon inflation time (40 ﾱ44 s
vs. 26 ﾱ27 s; p = 0.02) and the proportion of treated type C lesions (42% 
vs. 28%; p = 0.03). In multivariate analysis, the independent predictors of PMI
were balloon inflation time (OR = 1.01; 95% CI 1.001-1.020; p = 0.02) and pre-
procedural level of C-reactive protein (OR = 1.38; 95% CI 1.059-1.808; p = 0.02).
C Co on nc cl lu us si io on ns s: :   These results suggest that C-reactive protein and balloon ischaemic
time are independent predictors of PMI in stable angina patients pre-treated
with statins.
K Ke ey y   w wo or rd ds s: :   C-reactive protein, stent, myocardial infarction.
Introduction
Post-interventional cardiac marker release is considered to represent
peri-procedural myocardial infarction (PMI), which is a relatively common
complication of percutaneous coronary intervention (PCI), mostly with
a silent clinical course [1]. Recently, a relationship has been reported
between PMI and long-term mortality [2, 3]. Therefore, the prevention of
PMI will improve the long-term PCI outcome. 
There is a growing body of evidence supporting beneficial cholesterol-
independent effects (“pleiotropic” effects) of statins that are largely
accounted for by a favourable action profile of statins on endothelial
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function, bioavailability of nitric oxide, inflammation,
thrombosis, apoptosis, platelet activation, pla  que
stability, arrhythmias, and angiogenesis [4, 5].
Additionally, Ridker et al. have recently demon  -
strated  reduction  of  cardiovascular  events  in
apparently healthy persons without hyper  lipidaemia
but with elevated C-reactive protein (CRP) treated
by rosuvastatin [6]. Although the studies inve  -
stigating the effect of statin pre-treatment on 
the incidence of PMI are inconclusive [7-10], on 
the basis of existing literature it seems to be
recommendable to start treating with statins all
patients with coronary artery disease imme  diately,
irrespective of possible coronary inter  vention.
Since the crucial point of PMI management is
prevention,  a lot  of  approaches  including  the
determination of PMI predictors have been studied
up to now [11-13]. This retrospective study was
designed to determine the predictors of PMI in
stable patients pre-treated with statins undergoing
elective PCI.
Material and methods
Prospectively collected data on 418 patients with
stable angina pectoris or evidence of inducible
myocardial ischaemia in a cardiac stress test, who
were referred for percutaneous coronary inter  -
vention (PCI) of a de-novo lesion 50-90% of luminal
diameter, were retrospectively analysed in this
study.  Patients  suffering  from  acute  coronary
syndromes in the preceding three weeks were
excluded. All the patients had to be pre-treated with
statins and aspirin for ≥ 2 days. Statins used prior
to PCI are summarized in Table I. All study protocols
were approved by the local ethics committee, and
all the patients provided written informed consent. 
Stenoses that reduced the lumen diameter by
50% (visual estimation) or more were considered
significant. Quantitative coronary analysis was used
only when the assessment of two cardiologists was
disparate, with regard to categorization of lesion
severity  ≥ 50%.  The  coronary  artery  tree  was
divided into three compartments (left anterior
descending artery, left circumflex artery, and right
coronary artery) for categorization of one, two, and
three vessel coronary artery disease. Coronary
lesions were classified as either type A (discrete,
concentric), B1 (tubular, eccentric), B2 (irregular
contour, moderately angulated, calcified, bifurcation
requiring double wiring), or C (diffusely diseased
artery, long lesion, extremely angulated, inability to
protect significant side branch).
A weight-adjusted  bolus  of  heparin  was 
given routinely at the beginning of the procedure
(70-100 IU/kg), to keep the clotting time within 
250-300 s. Intracoronary isosorbide dinitrate was
administered  (0.2-0.5  mg)  just  prior  to  PCI.
Clopidogrel was given either in a loading dose 
(300-600 mg) one day before (in 96% of patients)
or immediately after the PCI. Glycoprotein IIb/IIIa
inhibitors were not used in this study. Numbers of
treated lesions and inflations were determined by
the operators as clinically indicated. Stent delivery
was routinely followed by high-pressure balloon
inflations (> 15 atm). In selected cases, direct
coronary stenting was used. Balloon ischaemic time
included the whole time in which the treated artery
was  occluded  by  an  inflated  balloon  catheter
(balloon dilation or stent implantation). Technical
success was defined as residual diameter stenosis
<  20%  by  visual  estimation  and  the  ultimate
achievement  of  thrombolysis  in  myocardial
infarction (TIMI) flow grade 3. 
The primary end-point of this study was the
occurrence of PMI as determined by the post-
interventional release of troponin I (TnI), and/or
creatine kinase-MB (CK-MB) mass ≥ 3 times upper
limit of normal. Blood samples were taken prior to
the PCI and then within 16-24 h thereafter. In
patients experiencing myocardial infarction within
24 h following the PCI, further measurements were
taken 48 h after the PCI. The patients were divided
into two groups (PMI group and non-PMI group)
according to the presence of PMI, and these groups
were compared. 
Continuous variables are expressed as mean ﾱ SD,
discrete variables as counts and/or percentages.
Differences between group characteristics were
compared using the ˇ2 test (Fisher’s exact test) for
categorical  variables  and  Student’s  test  for
continuous variables. The Mann-Whitney U test was
used  to  analyse  the  difference  between  the
medians in both groups of patients. The degree of
association between the post-procedural TnI and
T Ty yp pe e   o of f   s st ta at ti in n P PM MI I    N No on n- -P PM MI I    P P v va al lu ue e
( (n n = =   5 52 2) ) ( (n n   = =   3 36 66 6) )
Atorvastatin 10 mg/day [%] 66 NS
Atorvastatin 20 mg/day [%] 21 15 NS
Atorvastatin 40 mg/day [%] 63 NS
Atorvastatin 80 mg/day [%] 00 NS
Fluvastatin 20 mg/day [%] 02 NS
Fluvastatin 40 mg/day [%] 20 NS
Fluvastatin 80 mg/day [%] 26 NS
Simvastatin 10 mg/day [%] 44 NS
Simvastatin 20 mg/day [%] 44 58 NS
Simvastatin 40 mg/day [%] 15 5 0.004
Lovastatin 20 mg/day [%] 01 NS
T Ta ab bl le e   I I. . Statins used prior to percutaneous coronary
intervention
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CRP level (balloon inflation time) was calculated by
Spearman rank correlation. Multivariate analy  -
ses were performed using a logistic regression 
to  identify  predictors  of  PMI  based  on  post-
interventional release of TnI and/or CK-MB mass.
The variables included in the logistic regression
analysis are as follows: age, gender, diabetes,
hypertension, history of MI, total cholesterol level,
HDL-cholesterol  level,  LDL-cholesterol  level,
triglyceride level, C-reactive protein (hs-CRP) level,
clopidogrel pre-treatment, treatment of type C
lesion,  balloon  ischaemic  time.  Since  the  raw 
hs-CRP data were asymmetrical, the logarithmic
transformation  (log  CRP)  was  used  to  obtain
a normal distribution. The results of multivariate
analysis were described as odds ratios (OR) with
95% confidence interval (95% CI). A p-value of 
< 0.05 was considered statistically significant. 
Results
A total of 418 patients with stable angina pectoris
were eligible and underwent PCI. No patient died
during the hospital stay. Fifty-two (12%) patients
suffered from PMI based on TnI (48 pts.) and/or CK-
MB mass (21 pts.) release. These patients constituted
the PMI group. The incidence of PMI, based on
biomarkers release, are summarized in Table II. 
The baseline clinical variables were comparable
between the PMI and non-PMI group (Table III).
Angiographic and procedural characteristics were
similar in both groups, except for higher occurrence
of treated type C lesions (42% vs. 28%; p = 0.03)
and longer balloon inflation time (40 ﾱ44 s vs. 
26 ﾱ27 s; p = 0.02) (Table IV).
Multivariate analysis was performed to identify
the predictors of PMI, as was pre-specified. In this
model, only balloon inflation time (OR = 1.01; 95%
CI 1.001-1.020; p = 0.02) and pre-procedural level of
log CRP (OR = 1.38; 95% CI 1.059-1.808; p = 0.02)
were identified as independent predictors of PMI
(Table V). There was a weak correlation between
hs-CRP and post-procedural TnI levels (r = 0.15; 95%
CI 0.05-0.27; p = 0.017) (Figure 1). Similarly, there
was a statistically significant correlation between
TnI level and balloon ischaemic time (r = 0.32; 95%
CI 0.09-0.52; p = 0.007) (Figure 2).
Discussion
To the best of our knowledge, this is the first
study to date evaluating predictors of PMI in stable
angina pectoris patients taking aspirin and statins.
The results of this study suggest that CRP and
balloon  inflation  time  are  independent  pre-
procedural  and  procedural  predictors  of  PMI,
respectively.
Previously, pre-procedural risk predictors for 
PMI,  such  as  age,  acute  coronary  syndromes, 
HDL-cholesterol level, and inflammatory markers,
have been reported [11, 13, 14]. Similarly, procedural
risk factors for PMI, such as multivessel disease,
complex lesions and interventional complications
(coronary dissection, embolization or occlusion)
have been determined [11]. On the other hand, it
was  hypothesized  that  pre-procedural  statin
treatment decreases the extent of PMI as a function
of  myocardial  inflammatory  cell  accumulation
T Ty yp pe e   o of f   s st ta at ti in n P PM MI I    N No on n- -P PM MI I    P P v va al lu ue e
( (n n = =   5 52 2) ) ( (n n   = =   3 36 66 6) )
B Ba as se el li in ne e
Troponin I [ng/ml]
Median 0.1 0.1 NS
Interquartile range 0.1-0.1 0.1-0.1
CK-MB mass [ng/ml]
Median 1.6 1.1 NS
Interquartile range 0.868-2.045 0.735-1.67
P Po os st t- -P PC CI I
Troponin I [ng/ml]
Median 2.611 0.5 < 0.01
Interquartile range 1.7-5.368 0.1-0.5
CK-MB mass [ng/ml]
Median 6.22 1.22 < 0.01
Interquartile range 4.65-11.11 0.7-1.83
T Ta ab bl le e   I II I. . Incidence of peri-procedural myocardial
infarction based on TnI and CK-MB mass release
PMI – procedural myocardial infarction
T Ty yp pe e   o of f   s st ta at ti in n P PM MI I    N No on n- -P PM MI I    P P v va al lu ue e
( (n n = =   5 52 2) ) ( (n n   = =   3 36 66 6) )
Sex (male) [%] 71 68 NS
Angina pectoris class (CCS) 1.5 ﾱ1.4 1.8 ﾱ1.2 NS
History of myocardial  60 54 NS
infarction [%]
Smokers [%] 27 30 NS
Hypertension [%] 77 75 NS
Total plasma cholesterol  4.2 ﾱ1.1 4.6 ﾱ2.2 NS
[mmol/l]
LDL cholesterol [mmol/l] 3 ﾱ0.8 2.7 ﾱ0.9 NS
HDL cholesterol [mmol/l] 1.1 ﾱ0.4 1.1 ﾱ0.4 NS
Plasma triglyceride  1.6 ﾱ1.0 1.8 ﾱ1.2 NS
[mmol/l]
Diabetes mellitus [%] 29 33 NS
Hs-CRP [mg/l],  1.35  1.1  NS
median (IQR) (0.5-6.03) (0.5-3.95)
T Ta ab bl le e   I II II I. .   Baseline clinical characteristics of PMI and
non-PMI group
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resulting from reduction of adhesion molecule
expression  in  ischaemic  myocardium,  and  an
increase in the bioavailability of nitric oxide in the
coronary microvasculature [4, 7, 8, 10, 11]. Moreover,
some investigations have demonstrated reduction
of inflammatory markers within 24 h following
a single dose of statin administration [15]. Although
the role of pre-treatment with statins in patients
undergoing PCI for stable angina pectoris is not
clear, all the enrolled patients were pre-treated with
statins at least for two days prior to PCI.
Procedural myocardial infarction remains clini  -
cally silent in the vast majority of cases and its only
manifestation is the subsequent release of bio  -
markers of myocardial injury. As demonstrated
repeatedly, the incidence of PMI is substantially
dependent on the cut-off value of chosen bio  -
markers, marker assay, and frequency of blood
analyses. In non-selective, multimarker series, the
incidence of PMI ranged from 1% to 49% [11]. 
C-reactive protein has been widely considered
to be a non-specific but sensitive marker of acute
inflammatory response. Ridker et al. suggested 
that measurement of CRP may provide a useful
method of assessing the risk of cardiovascular
disease in apparently healthy persons, and even in
patients prior to PCI [16]. However, it seems to be
likely that CRP level is not related directly to the
extent  of  coronary  atherosclerosis  but  more
substantially to vulnerability of atherosclerotic
plaques [17, 18]. Therefore, CRP by some undefined
mechanism influences the outcome of PCI, even in
patients  with  stable  coronary  artery  disease.
Saadeddin et al. found pre-procedural CRP elevation
in 41% of patients with stable angina undergo    -
ing PCI, associated with 2.3-fold higher risk of
developing PMI. However, because of the small size
of  the  patient  cohort  enrolled  in  their  study 
(n = 85), the validity of their conclusion seems to
be limited [14]. Interestingly, Park et al. demon  -
strated the association of pre-procedural CRP level
higher than normal (≥ 3 mg/l) with the incidence
of drug-eluting stent thrombosis during the 3.9-year
O Od dd ds s   r ra at ti io o   ( (9 95 5% %   C CI I) ) P P v va al lu ue e
Age 1.03 (0.98-1.08) NS
Gender 1.98 (0.76-5.13) NS
Hypertension 0.87 (0.37-2.08) NS
History of myocardial  1.57 (0.71-3.46) NS
infarction
Total cholesterol 0.87 (0.39-1.95) NS
HDL cholesterol 1.62 (0.56-4.71) NS
LDL cholesterol 1.15 (0.52-2.55) NS
Triglyceride 0.81 (0.50-1.32) NS
Log hs-CRP 1.38 (1.06-1.81) 0.02
Clopidogrel pre-treatment 0.59 (0.26-1.32) NS
Type C lesion 1.12 (0.43-2.90) NS
Balloon ischaemic time 1.01 (1.00-1.02) 0.02
T Ta ab bl le e   V V. . Predictors of peri-procedural myocardial
infarction
T Ty yp pe e   o of f   s st ta at ti in n P PM MI I    N No on n- -P PM MI I    P P v va al lu ue e
( (n n = =   5 52 2) ) ( (n n   = =   3 36 66 6) )
Lesion located in LAD, LCx, RCA, SVG, LMCA [%] 44/37/23/0/2 38/30/31/1/4 NS
One/two/three-vessel disease [%] 40/21/37 43/32/24 NS
Lesions
A [%] 65 NS
B1 [%] 21 28 NS
B2 [%] 25 33 NS
C [%] 42 28 0.03
Stenosis of treated lesions [%] 86 ﾱ10 83 ﾱ10  NS
Intracoronary thrombosis [%] 15 7 NS
Treated lesions [mean] 1.3 ﾱ0.5 1.2 ﾱ0.5 NS
Stented patients [%] 88 83 NS
Stents per patient [%] 1.2 ﾱ0.2 1.1 ﾱ0.2 NS
Balloon inflation time [s] 40 ﾱ44 26 ﾱ27 0.02
Angiographic success [%] 99 100 NS
Acute main or side branch occlusion [%] 61 NS
Reintervention within 24 h [n]0 1 NS
T Ta ab bl le e   I IV V. . Angiographic and interventional characteris  tics of the study population
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follow-up of electively treated patients with stable
angina [19]. Moreover, Briguori et al. showed that
a single high loading dose of atorvastatin reduces
the incidence of PMI in elective PCI, especially in
high CRP level patients [10]. On the other hand,
a recent meta-analysis by Kinlay suggested that
most  of  the  anti-inflammatory  effect  of  LDL-
lowering therapies is related to the magnitude of
change in LDL cholesterol. Thus, the potential non-
LDL (“pleiotropic”) effects of statins on inflam  -
mation  are  much  smaller  in  magnitude  than
thought before [20]. Nevertheless, with an improved
understanding of the pathophysiology of athe  -
rothrombosis, advanced technology, and an in  -
creased ability to efficiently screen and reliably
measure molecular, cellular, and other blood-borne
biomarkers, the overall role of biomarkers including
CRP in clinical decision making is expected to
expand exponentially [21].
Although all the patients in our study were pre-
treated with statins for at least two days before PCI,
the  level  of  pre-procedural  CRP  remains  an
important risk factor for elective PCI. Therefore,
based on these results it seems to be reasonable
to include CRP in the clinical decision-making
process and timing of PCI in patients with stable
angina pectoris. We could hypothesize that in
patients with a high CRP level the elective PCI might
be postponed, and patients should be pre-treated
aggressively with statins to reduce the CRP level as
much as possible.
Balloon  ischaemic  time  proved  to  be  an
independent procedural predictor of PMI in this
study. However, this finding must be understood in
the context of design of this retrospective study.
Since a fair number of procedure-related risk factors
were not recorded, it seems likely that we might
have missed the opportunity to identify additional
procedural predictors of PMI. Thus, on the basis of
existing  data,  balloon  ischaemic  time  as  an
independent PMI predictor might represent not only
longer duration of procedural myocardial ischaemia,
but  also  more  complex  intervention  that  was
caused by more complex initial coronary findings.
Moreover, balloon inflation time was a statistically
significant predictor of PMI, but its odds ratio was
only 1.01 (95% CI 1.001-1.020; p = 0.02). Therefore,
based on these data its role in pathophysiology 
of PMI seems to be rather limited.
S St tu ud dy y   l li im mi it ta at ti io on ns s
The present study has several limitations. First,
the limited number of enrolled patients and low
incidence of PMI resulted in a relatively small size
of the PMI group (52 pts.). Therefore, a type II
statistical error cannot be ruled out definitely and
some additional factors might play a significant role
in the pathophysiology of the PMI. Moreover, the
analyses of subgroups have in this study only
minimal relevance. Therefore, a statistically sig  -
nificant  difference  in  the  incidence  of  PMI  in
patients pre-treated with simvastatin 40 mg cannot
be considered a result of this study. Second, this
study  analysed  retrospectively  data  collected
prospectively. In this light it has to be understood
that at the time of intervention not all parameters
of  possible  interest  were  recorded.  Thus,  any
generalizations based on our results should be
made  with  caution.  Third,  blood  samples  for
biomarkers were taken prior to the PCI and then
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design cannot rule out for certain any additional
events that would be detected within 24-48 h after
the PCI. Fourth, data on the duration of statin pre-
treatment longer than two days are not available.
These results suggest that C-reactive protein and
balloon ischaemic time are independent predictors
of PMI in stable angina patients on statin therapy.
Future studies are required to determine whether
the reduction of CRP level should be recommended
prior to elective PCI.
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